Leo Wealth LLC Buys 1,438 Shares of Sanofi (NASDAQ:SNY)

Leo Wealth LLC lifted its position in shares of Sanofi (NASDAQ:SNY) by 6.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,182 shares of the company’s stock after purchasing an additional 1,438 shares during the period. Leo Wealth LLC’s holdings in Sanofi were worth $1,451,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Stablepoint Partners LLC boosted its holdings in Sanofi by 0.8% in the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after acquiring an additional 189 shares during the last quarter. TCTC Holdings LLC boosted its stake in shares of Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after purchasing an additional 210 shares during the last quarter. HB Wealth Management LLC increased its position in shares of Sanofi by 3.7% during the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after buying an additional 221 shares during the period. Insigneo Advisory Services LLC raised its stake in Sanofi by 3.3% during the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after buying an additional 228 shares during the last quarter. Finally, Pinnacle Bancorp Inc. lifted its holdings in Sanofi by 24.6% in the third quarter. Pinnacle Bancorp Inc. now owns 1,227 shares of the company’s stock valued at $71,000 after buying an additional 242 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Down 0.5 %

Sanofi stock traded down $0.29 during midday trading on Tuesday, reaching $53.37. The stock had a trading volume of 1,199,165 shares, compared to its average volume of 2,016,707. The company has a fifty day moving average price of $56.13 and a two-hundred day moving average price of $51.62. Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $135.17 billion, a P/E ratio of 26.71, a PEG ratio of 1.57 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. During the same quarter in the previous year, the company posted $0.95 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. As a group, equities analysts expect that Sanofi will post 4.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. Argus lifted their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 14th. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.